Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells $293,949.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.87, for a total value of $293,949.00. Following the transaction, the insider now owns 301,808 shares of the company’s stock, valued at $32,857,836.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $109.66, for a total value of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total value of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $89.55, for a total value of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00.

Natera Trading Up 0.8 %

Shares of NTRA stock opened at $111.64 on Friday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $117.23. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The company’s fifty day moving average price is $106.10 and its two-hundred day moving average price is $87.05.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. During the same quarter in the previous year, the business posted ($1.23) EPS. The firm’s revenue was up 52.1% compared to the same quarter last year. On average, research analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on NTRA. The Goldman Sachs Group lifted their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Robert W. Baird lifted their target price on shares of Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. Piper Sandler lifted their target price on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 14th. Finally, BTIG Research boosted their price objective on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, May 13th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.19.

Hedge Funds Weigh In On Natera

Institutional investors have recently added to or reduced their stakes in the company. RiverPark Advisors LLC acquired a new position in Natera in the 4th quarter worth $27,000. Principal Securities Inc. acquired a new stake in shares of Natera in the 4th quarter valued at about $32,000. GAMMA Investing LLC raised its stake in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. YHB Investment Advisors Inc. acquired a new stake in shares of Natera in the 1st quarter valued at about $36,000. Finally, Oliver Lagore Vanvalin Investment Group raised its stake in shares of Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.